Kenvue Inc.

Equities

KVUE

US49177J1025

Personal Products

Delayed Nyse 03:50:18 2024-05-17 pm EDT 5-day change 1st Jan Change
20.46 USD -0.66% Intraday chart for Kenvue Inc. -0.29% -4.88%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Ten key beauty players Our Logo
Kenvue Prices Secondary Common Stock Offering MT
Top Midday Stories: Return of 'Roaring Kitty' Lifts GameStop Shares; Intel, Apollo Near Deal on Ireland Plant; BHP Latest Offer Rejected by Anglo American; Squarespace Acquired by Permira; Amazon Autonomous Driving Under Probe MT
J&J: stake in Kenvue to be sold off CF
J&J to Sell Remaining Stake in Kenvue Spinoff DJ
Sector Update: Consumer Stocks Gain Premarket Monday MT
Johnson & Johnson to No Longer Own Kenvue Shares After Proposed Offering Closes MT
Johnson & Johnson to No Longer Own Kenvue Shares After Proposed Offering Closes MT
J&J to exit Kenvue, a year after spinoff RE
J&J to sell all shares in spun-off unit Kenvue RE
HSBC Adjusts Price Target on Kenvue to $21 From $20 MT
Health Care Up Amid Mixed Earnings - Health Care Roundup DJ
News Highlights : Top Company News of the Day - Tuesday at 3 PM ET DJ
News Highlights : Top Company News of the Day - Tuesday at 1 PM ET DJ
Wall St set to stall at open after recent run RE
Transcript : Kenvue Inc., Q1 2024 Earnings Call, May 07, 2024
Kenvue's Q1 Adjusted Earnings Decline, Revenue Rises; 2024 Outlook Reiterated; Shares Rise Pre-Bell MT
Earnings Flash (KVUE) KENVUE Posts Q1 Revenue $3.89B, vs. Street Est of $3.79B MT
Earnings Flash (KVUE) KENVUE Reports Q1 EPS $0.28, vs. Street Est of $0.25 MT
Tylenol maker Kenvue beats quarterly profit estimates, to cut 4% jobs RE
Kenvue Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Kenvue Inc. Re-Affirms Earnings Guidance for the Year 2024 CI
Kenvue's Q1 Challenges Prompt Investor Caution; Visibility May Alter Sentiment, UBS Says MT
Kenvue Declares Quarterly Cash Dividend, Payable on May 22, 2024 CI
Contaminated cough syrup in Africa no longer available - WHO RE
Chart Kenvue Inc.
More charts
Kenvue Inc. is one of the world leaders in the design, manufacture and marketing of consumer healthcare products. The group offers products for health, beauty, baby care, oral care, skin care and more. The business is organized around 3 product families: - health products: for the treatment of coughs, colds, allergies, pain, indigestion, constipation, etc. (brands Zyrtec, Benadryl, Zarbee's, Frenadol, Codral, Reactine, Tylenol, Motrin, Calpol, Nicorette, Imodium, Pepcid, Microlax, Daktarin, etc.); - body care products: hair care products, sun protection products, face and body care products, etc. (Neutrogena, Aveeno, Clean&Clear, Lubriderm, Johnsons, Neostrata, OGX, Rogaine brands, etc.); - other: notably oral care, baby care, women's health and wound care products (Listerine, Desitin, Carefree, Stayfree, Band-Aid, Neosporin brands, etc.). Product marketing is assured through direct sales, distributors and the Internet.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
20.6 USD
Average target price
22.71 USD
Spread / Average Target
+10.25%
Consensus
  1. Stock Market
  2. Equities
  3. KVUE Stock
  4. News Kenvue Inc.
  5. William Blair Initiates Kenvue With Market Perform Rating
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW